
TRAIN Newsletter — September 2022

Letter of Support: Reauthorization of Food and Drug Administration (FDA) User Fee Programs

Mapping the Patient and Caregiver Journey for Cell and Gene Therapies

Comments on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products, Federal Register Docket FDA-2016-D-3561

TRAIN Newsletter — June 2023

Statement at Multi-Stakeholder meeting in support of the UN High-Level Meeting on Pandemic Prevention, Preparedness and Response

Food and Drug Administration (FDA) - Patient Perspectives on Gene Therapy Products

TRAIN Newsletter — September 2023

TRAIN Newsletter — June 2022

Milken Institute statement on ARPA-H inclusion in FY2022 spending bill
